Company Description
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lav...
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Valuation
Price to Sales Ratio
111.38
Price to Book Ratio
5.67
Enterprise Value to EBITDA
-11.91
Enterprise Value to Sales
31.22
Efficiency
Total Asset Turnover
0.03
Liquidity
Current Ratio
2.37
Quick Ratio
2.37
Cash Ratio
2.29
Profitability
Gross Margin
88.47
Operating Margin
-607.78
Pretax Margin
-598.34
Net Margin
-597.15
Return on Assets
-19.32
Return on Equity
-27.51
Return on Total Capital
-26.34
Capital Structure
Total Debt to Total Assets
4.56
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Ryan J. Watts | 43 | 2013 | President, Director & Chief Scientific Officer |
Dr. Alexander O. Schuth | 47 | 2013 | Chief Operating Officer |
Dr. Joe Lewcock | - | 2020 | Chief Scientific Officer |
Dr. Carole Ho | 48 | 2015 | Chief Medical Officer & Head-Development |
Dr. Dana Andersen | - | 2018 | CTO & Chief Manufacturing Officer |
Insider Actions
01/17/2023 |
Alexander O. Schuth COFO and Secretary |
114 | Disposition at $29.87 per share. | 3,405 |
01/17/2023 |
Alexander O. Schuth COFO and Secretary |
9,886 | Disposition at $29.53 per share. | 291,933 |
01/17/2023 |
Alexander O. Schuth COFO and Secretary |
10,000 | Derivative/Non-derivative trans. at $5.28 per share. | 52,800 |
01/09/2023 |
Carole Ho Chief Medical Officer |
1,459 | Disposition at $28.48 per share. | 41,552 |
01/06/2023 |
Carole Ho Chief Medical Officer |
1,451 | Disposition at $28.67 per share. | 41,600 |
01/05/2023 |
Ryan J. Watts President and CEO; Director |
4,800 | Disposition at $28.44 per share. | 136,512 |
01/05/2023 |
Steve E. Krognes Director |
2,970 | Disposition at $28.44 per share. | 84,466 |
01/05/2023 |
Alexander O. Schuth COFO and Secretary |
2,636 | Disposition at $28.44 per share. | 74,967 |
01/05/2023 |
Carole Ho Chief Medical Officer |
2,636 | Disposition at $28.44 per share. | 74,967 |
01/04/2023 |
Ryan J. Watts President and CEO; Director |
5,029 | Disposition at $28.73 per share. | 144,483 |
01/04/2023 |
Alexander O. Schuth COFO and Secretary |
2,912 | Disposition at $28.7 per share. | 83,574 |
01/04/2023 |
Alexander O. Schuth COFO and Secretary |
2,912 | Disposition at $28.7 per share. | 83,574 |
01/04/2023 |
Carole Ho Chief Medical Officer |
2,913 | Disposition at $28.69 per share. | 83,573 |
01/03/2023 |
Ryan J. Watts President and CEO; Director |
82,240 | Award at $0 per share. | 0 |
01/03/2023 |
Alexander O. Schuth COFO and Secretary |
41,120 | Award at $0 per share. | 0 |
01/03/2023 |
Carole Ho Chief Medical Officer |
41,120 | Award at $0 per share. | 0 |
11/23/2022 |
Marc Tessier-Lavigne Director |
20,000 | Disposition at $30.48 per share. | 609,600 |
11/02/2022 |
Marc Tessier-Lavigne Director |
11,252 | Disposition at $30.33 per share. | 341,273 |
11/01/2022 |
Marc Tessier-Lavigne Director |
8,748 | Disposition at $30.2 per share. | 264,189 |
10/07/2022 |
Alexander O. Schuth COFO and Secretary |
20,000 | Derivative/Non-derivative trans. at $0.68 per share. | 13,600 |
MarketWatch News on DNLI
-
Denali Therapeutics stock price target cut to $41 from $60 at Stifel Nicolaus
- Tomi Kilgore
-
4 Beaten-Down Biotech Stocks That Could Take Off
- Barron's Online
-
Denali Therapeutics started at outperform with $85 stock price target at Oppenheimer
- Tomi Kilgore
-
Biogen's Alzheimer's Drug Is Approved by the FDA
- Barron's Online
-
What to Know About the FDA's Approval of Biogen's Alzheimer's Drug
- Barron's Online
-
Don’t Expect Amazon Prime Day to Move the Stock
- Barron's Online
-
The FDA's Biogen Decision Will Cause Waves Across Biotech
- Barron's Online
-
Denali Therapeutics started at buy with $70 stock price target at UBS
- Tomi Kilgore
-
Biotech stocks are a buy — especially these 18 picks
- Michael Brush
-
The 12 Most Overpriced Stocks in America
- Barron's Online
-
Denali down 10% on pause in neurological drug
- MarketWatch.com
-
- Barron's Online
-
Denali Therapeutics upgraded to outperform from neutral at Wedbush
- Tomi Kilgore
-
Denali Therapeutics started at hold with $26 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
Denali Therapeutics started at neutral with $19 stock price target at Wedbush
- Tomi Kilgore
-
Denali Therapeutics started at buy with $35 stock price target at Instinet
- Tomi Kilgore
-
Jeffrey Epstein’s Investing Lagged Behind the Market
- Barron's Online
- Loading more headlines...
Other News on DNLI
-
10-Q: DENALI THERAPEUTICS INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Tracking Baillie Gifford's 13F Portfolio - Q3 2022 Update
- Seeking Alpha
-
Clarius Group, LLC Buys 3, Sells 2 in 3rd Quarter
- GuruFocus.com
-
Denali Therapeutics prices $275M stock offering
- Seeking Alpha
-
Baron Growth Fund Q2 2022 Shareholder Letter
- Seeking Alpha
-
3 Companies Growing Revenue Fast
- GuruFocus.com
-
10-Q: DENALI THERAPEUTICS INC.
- Edgar Online - (EDG = 10Q, 10K)
- Loading more headlines...